Agendia brings new personalized treatment for breasts cancer patients Agendia, a global leader in molecular cancers diagnostics, today announced that its breast cancer product offering, comprising breast cancer recurrence test MammaPrint, and TargetPrint, has been expanded with BluePrint to record important more information on tumor subtypes. This fresh service is founded on an 80-gene signature that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancers tumors. Using BluePrint, we will research potentially different responses of therapies to different subgroups together with our customers biologically.Seitz added that countries like the United Germany and Kingdom possess even greater problems, especially with binge drinking. ‘The public has to recognize that alcohol is a major health problem, that alcohol is the number one element for liver disease in European countries, and that if we want to control this nagging problem a number of measures have to be taken, such as raising the price of alcoholic beverages and reducing their availability,’ stated Seitz. ‘Clinicians have to be aware of alcoholic liver disease, and that there exists a need for early intervention and recognition. Furthermore, many clinicians and also the public have no idea that alcoholic beverages is a significant risk factor for cancers of the mouth, larynx, pharynx, esophagus, liver, female breast, and the colorectum – cancers with a high prevalence inside our societies.’.
Chewing Tobacco Kills More Than 250,000 People Each Year: Report: – WEDNESDAY, Sept.